OppFi's $130M acquisition of BNCCORP and Enova's proposed purchase of Grasshopper Bancorp face challenges from 20 state attorneys general concerned these deals could bypass state interest-rate caps by leveraging national bank charters. Both companies project significant financial synergies from cheaper funding and geographic expansion, with OppFi expecting over $60 million in first-year synergies and Enova projecting up to $230 million in revenue synergies within two years. The states argue these high rates, sometimes reaching 195%, could harm borrowers and raise safety concerns due to high default rates. Regulatory approval conditions could impact the deals' financial benefits, making the outcome critical for the companies' expansion and cost-saving strategies.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Replimune Group's stock fell sharply by 38.01% following FDA briefing documents that deemed its skin cancer drug trial data "not interpretable," signaling a major regulatory setback. Other companies like Travelzoo and Amkor Technology also saw signif...
